價格 | 詢價 | ||
包裝 | 100ug | 500ug | 1000ug |
最小起訂量 | 100ug |
發(fā)貨地 | 北京 |
更新日期 | 2024-11-12 |
中文名稱:CD109蛋白 | 英文名稱:CD109 |
品牌: 百普賽斯 | 產(chǎn)地: 北京 |
保存條件: -20°C to -70°C | 純度規(guī)格: 99.9% |
產(chǎn)品類別: 重組蛋白 | |
貨號: CD109 | 用途范圍: 藥物開發(fā)等 |
規(guī)格: 100ug | 是否進口: 否 |
英文名稱:DNA polymerase alpha subunit
中文名稱:DNA聚合酶α亞基
靶點別稱:CD109,CPAMD7
物種:Human
標簽:His Tag & Avi Tag
屬性:Protein
標記:Biotin-labeled
表達區(qū)間及表達系統(tǒng)(Source)
Biotinylated Human CD109, His,Avitag (CD9-H82E4) is expressed from human 293 cells (HEK293). It contains AA Val 22 - Ser 1269 (Accession # Q6YHK3-1).
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 143.5 kDa. The protein migrates as 150-170 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標記(Labeling)
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標記度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
CD109是一種糖基磷脂酰肌醇(GPI)連接的糖蛋白,定位于血小板、活化T細胞和內(nèi)皮細胞的表面。CD109在許多惡性腫瘤中表達,包括各種鱗狀細胞癌和腺癌,并作為多功能輔助受體發(fā)揮作用。據(jù)報道,CD109與轉(zhuǎn)化生長因子(TGF)-β受體相關(guān),并負調(diào)控角質(zhì)形成細胞中的TGF-β信號傳導(dǎo)。此外,CD109可能與信號轉(zhuǎn)導(dǎo)子和轉(zhuǎn)錄激活子-3信號傳導(dǎo)和異常細胞增殖有關(guān)。
成立日期 | 2010-07-22 (15年) | 注冊資本 | 8000萬人民幣 |
員工人數(shù) | 500人以上 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 醫(yī)藥中間體,原料藥,激素類,氨基糖苷類,中樞神經(jīng)系統(tǒng)用藥 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥2616 |
VIP5年
|
上海澤葉生物科技有限公司
|
2024-11-18 | |
詢價 |
VIP4年
|
上海冠導(dǎo)生物工程有限公司
|
2024-11-18 | |
¥3104 |
VIP4年
|
上海博爾森生物科技有限公司
|
2024-11-18 |